<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nonlactational mastitis in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nonlactational mastitis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nonlactational mastitis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Michael Dixon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth M Pariser, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sandra Nelson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 04, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mastitis refers to inflammation of the breast tissue that may or may not be accompanied by infection. Mastitis does not necessarily occur during lactation, is not always accompanied by microbial infection, and may not resolve with antibiotics. Forms of nonlactational mastitis include periductal mastitis and idiopathic granulomatous mastitis.</p><p>Issues related to nonlactational mastitis in adults will be reviewed here; issues related to lactational mastitis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/798.html" rel="external">"Lactational mastitis"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">PERIDUCTAL MASTITIS</span><span class="headingEndMark"> — </span>Periductal mastitis is an inflammatory condition of the subareolar ducts; the cause is unknown. Periductal mastitis primarily affects young women but can occur in men as well.</p><p>The majority of patients with periductal mastitis are smokers. It has been postulated that smoking is associated with damage of the subareolar ducts, with tissue necrosis and subsequent infection [<a href="#rid1">1,2</a>]. The toxic substances in cigarette smoke may damage the ducts directly or there may be a localized hypoxic effect. In a study of 139 patients with the clinical or pathologic diagnosis of periductal mastitis, 89 percent were smokers (as compared with 39 percent of age-matched controls). The breast concentrates substances in cigarette smoke; cotinine, a nicotine derivative, has higher concentrations in subareolar ducts than in plasma [<a href="#rid3">3-5</a>].</p><p>Periductal mastitis is also associated with squamous metaplasia, which is likely a consequence of ongoing inflammation. It has been suggested that squamous metaplasia may lead to partial duct obstruction with subsequent dilatation and secondary inflammation and infection [<a href="#rid2">2,6,7</a>]. However, as normal ducts are blocked by keratin, it is the author's view that duct obstruction, duct dilatation, and squamous metaplasia are not precursors of periductal inflammation or relevant etiologic factors.</p><p class="headingAnchor" id="H13"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Periductal mastitis is an inflammatory condition of the subareolar ducts that usually presents with periareolar inflammation [<a href="#rid1">1,2,8,9</a>]. Secondary infection of inflamed ducts can occur, leading to duct damage and subsequent rupture with abscess formation  (<a class="graphic graphic_picture graphicRef76304" href="/z/d/graphic/76304.html" rel="external">picture 1</a>). Such abscesses often drain spontaneously at the edge of the areola. Recurrent abscesses and a draining fistula (ie, communication between a major subareolar duct and the skin)  (<a class="graphic graphic_picture graphicRef78199 graphicRef58118 graphicRef65757 graphicRef75481" href="/z/d/graphic/78199.html" rel="external">picture 2A-D</a>) can occur [<a href="#rid3">3,6,10-12</a>]. (See <a class="local">'Subareolar abscess and periareolar fistula'</a> below.)</p><p class="headingAnchor" id="H4038682193"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of periductal mastitis is essentially clinical based on appearance. Ultrasound is typically performed to rule out abscess, if there is a mass or if signs of infection do not regress within a few days. Mammograms are not typically performed since they are less valuable and quite painful in the typically young patients in whom periductal mastitis occurs.</p><p class="headingAnchor" id="H12090387"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Periductal mastitis must be distinguished from duct ectasia, which usually affects older women and is characterized by distension of subareolar ducts with fibrosis [<a href="#rid13">13</a>]. Duct ectasia is associated with creamy or cheesy nipple discharge and nipple inversion  (<a class="graphic graphic_picture graphicRef57055" href="/z/d/graphic/57055.html" rel="external">picture 3</a>) [<a href="#rid14">14</a>]. The dilated subareolar ducts may be apparent clinically and visible on imaging [<a href="#rid15">15,16</a>].</p><p>Originally, duct ectasia and periductal mastitis were considered part of the same clinical syndrome and the two terms were used interchangeably. However, duct ectasia is an age-related phenomenon and is not associated with significant periareolar inflammation or infection. Few women with duct ectasia have a history of prior periductal mastitis.</p><p>Periductal mastitis must also be differentiated from breast cancer. (See  <a class="medical medical_review" href="/z/d/html/808.html" rel="external">"Diagnostic evaluation of suspected breast cancer"</a>.)</p><p class="headingAnchor" id="H12091176"><span class="h2">Microbiology</span><span class="headingEndMark"> — </span>Cultures are positive for pathogenic or potentially pathogenic organisms in 62 to 85 percent of cases [<a href="#rid17">17-19</a>]. In a series of 29 patients with periductal mastitis, pathogenic or potentially pathogenic organisms were observed more frequently in patients with nipple discharge and a periareolar mass than in patients with nipple discharge only (83 versus 27 percent, respectively) [<a href="#rid17">17</a>].</p><p>The most common organisms are staphylococci, enterococci, anaerobic streptococci, <em>Bacteroides</em>, and <em>Proteus</em>.</p><p class="headingAnchor" id="H14"><span class="h2">Management</span></p><p class="headingAnchor" id="H12093066"><span class="h3">Periductal mastitis</span><span class="headingEndMark"> — </span>Periductal mastitis is usually a chronic problem. In the setting of purulent nipple discharge, Gram stain and culture should be obtained. Approximately half of the cases resolve with antibiotic therapy together with needle aspiration or incision and drainage of any associated abscess [<a href="#rid7">7</a>]. Patients with repeated episodes of periareolar infection warrant surgical treatment with excision of diseased ducts [<a href="#rid20">20</a>]. (See <a class="local">'Subareolar abscess and periareolar fistula'</a> below.)</p><p>Empiric antibiotic therapy for periductal mastitis consists of <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> (875 mg orally every 12 hours). Reasonable alternative regimens include <a class="drug drug_general" data-topicid="9349" href="/z/d/drug information/9349.html" rel="external">dicloxacillin</a> (500 mg orally four times daily) or <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a> (500 mg orally four times daily; with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> [500 mg orally three times daily] if anaerobes are suspected) [<a href="#rid18">18,21</a>]. If risk for methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) is high  (<a class="graphic graphic_table graphicRef53504" href="/z/d/graphic/53504.html" rel="external">table 1</a>), <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (one double-strength tablet orally twice daily) or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily) is an appropriate regimen. In the setting of beta-lactam hypersensitivity, <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> (300 to 450 mg orally three times daily) is a reasonable alternative [<a href="#rid17">17,18</a>]. Therapy should be tailored to results of Gram stain and culture when available.</p><p>The optimal length of therapy is not certain; a 5- to 7-day course can be used if the response to therapy is rapid and complete; if necessary, the duration may be extended to 10 to 14 days.</p><p>Smoking cessation is helpful for reducing the risk of repeat infection [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H7391701"><span class="h3">Subareolar abscess and periareolar fistula</span><span class="headingEndMark"> — </span>These conditions are usually complications of periductal mastitis. The management of subareolar abscess consists of antibiotic therapy (see <a class="local">'Periductal mastitis'</a> above) and abscess drainage. Needle aspiration or incision and drainage of an abscess is associated with recurrence of subareolar abscess in up to half of patients [<a href="#rid3">3,7</a>]. Infection recurs because these procedures do not remove the underlying periductal mastitis [<a href="#rid1">1-4,22</a>]. In one study, 33 of 67 cases of subareolar abscess were treated successfully with needle aspiration and antibiotics; the other 34 patients required definitive duct excision to healthy tissue [<a href="#rid7">7</a>]. Similar results have been reported in other clinical series [<a href="#rid23">23</a>].</p><p>The management of periareolar fistula is laying open the fistula or excision of the fistula tract, usually combined with a total duct excision [<a href="#rid6">6-8,23,24</a>]. Multiple ducts may be involved with multiple skin openings in some patients; all need to be resected for cure [<a href="#rid25">25,26</a>].</p><p>Total ductal excision can often be performed with local anesthesia and sedation or under general anesthesia as an outpatient procedure. The preferred surgical approach is via a circumareolar incision at the 6 o'clock position, unless a previous scar exists, in which case the scar can be reopened. Dissection is performed underneath the areola and down either side of the major ducts. Curved tissue forceps can be passed around the ducts to facilitate delivery of the ducts into the incision. The ducts are then divided from the undersurface of the nipple and a 2 cm portion of duct is removed  (<a class="graphic graphic_picture graphicRef78199 graphicRef58118 graphicRef65757 graphicRef75481" href="/z/d/graphic/78199.html" rel="external">picture 2A-D</a>).</p><p>The back of the nipple must be cleared of all ducts right up to the nipple skin, as infection may recur unless all residual diseased ducts are removed. Sutures rarely, if ever, need to be placed behind the nipple to maintain eversion of the nipple. If the nipple does not evert after resection of the diseased ducts, further dissection and division of fibrous tissue may be required. Subcutaneous tissue can be closed with fine interrupted absorbable sutures and the skin is closed with a running subcuticular absorbable suture. Patients should understand that this procedure results in reduced nipple sensitivity in almost 40 percent of cases [<a href="#rid27">27</a>].</p><p>Antibiotic treatment for periductal mastitis should be initiated at the time of surgery and be continued postoperatively until all signs of infection have resolved. (See <a class="local">'Periductal mastitis'</a> above.)</p><p class="headingAnchor" id="H18"><span class="h1">IDIOPATHIC GRANULOMATOUS MASTITIS</span><span class="headingEndMark"> — </span>Idiopathic granulomatous mastitis (IGM), also known as idiopathic granulomatous lobular mastitis, is a rare benign inflammatory breast disease of unknown etiology [<a href="#rid1">1,22,28-35</a>]. It is usually unilateral, but in rare instances, it can be bilateral or develop later in the other breast.</p><p class="headingAnchor" id="H1167135348"><span class="h2">Epidemiology and pathogenesis</span><span class="headingEndMark"> — </span>IGM occurs most commonly in parous young women (within five years of pregnancy); it can also occur in nulliparous women and has been reported in men as well. </p><p>Women from Southeast Asia and the Middle East may have a higher incidence of IGM than those of European ancestry [<a href="#rid36">36</a>]. Among women in the United States, it has been associated with Hispanic ethnicity [<a href="#rid34">34,37</a>]. </p><p>Hyperprolactinemia, whether drug induced or associated with a prolactin-producing pituitary adenoma, has been associated with IGM [<a href="#rid38">38,39</a>]. </p><p>There is no increased risk of subsequent breast cancer in patients with IGM. </p><p>There may be an association between IGM and <em>Corynebacterium kroppenstedtii</em> infection especially, but not exclusively, with the histologic pattern termed cystic neutrophilic granulomatous mastitis [<a href="#rid40">40-44</a>]. Other <em>Corynebacterium</em> species have also been associated with IGM. In addition, mastitis due to <em>C. kroppenstedtii</em> has been associated with elevated prolactin levels [<a href="#rid45">45</a>]. Although antibiotics targeting <em>Corynebacterium</em> are often prescribed for IGM, there is no clear evidence that this approach alters the course of disease. Thus, corynebacteria may not be the causative factor in most patients with IGM.</p><p class="headingAnchor" id="H59659171"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>IGM may present as a solitary peripheral tender inflammatory breast mass; it can also present as multiple simultaneous peripheral masses (rarely central) with abscesses and/or overlying skin inflammation and ulceration  (<a class="graphic graphic_picture graphicRef51199" href="/z/d/graphic/51199.html" rel="external">picture 4</a>) [<a href="#rid1">1,28-32</a>]. Nipple retraction, sinus formation, peau d'orange-like changes, and axillary adenopathy may accompany these findings [<a href="#rid46">46-49</a>]. Women with IGM may develop repeated abscesses over weeks to months. These findings may be confused with breast abscess or malignancy [<a href="#rid28">28</a>].</p><p>Mammography may be suggestive of malignancy [<a href="#rid50">50-55</a>].</p><p class="headingAnchor" id="H59659178"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Ultrasound is the initial investigation of choice. Ultrasound examination typically demonstrates a solid mass, often with one or more abscesses. The diagnosis of IGM is established via core needle biopsy of a solid mass visualized on ultrasound. The biopsy should be sent for Gram stain, bacterial culture, acid-fast bacilli stain and culture, fungal stain and culture, and histopathology. The microbiology laboratory should be alerted to clinical concern for <em>Corynebacterium</em>.</p><p>Biopsy findings typically demonstrate non-necrotizing granulomatous lesions centered on the breast lobule.</p><p>It is also reasonable to obtain a serum prolactin level, given a possible pathogenic link between hyperprolactinemia and IGM [<a href="#rid45">45</a>]. Testing to exclude tuberculosis, sarcoidosis, and fungal diseases in the appropriate clinical setting is appropriate. Routine testing for autoantibodies is not recommended [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H2706044948"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis includes conditions such as tuberculosis, foreign body reaction, breast cancer, granulomatosis with polyangiitis, histoplasmosis, or rarely sarcoidosis, which may also induce a granulomatous mastitis. These etiologies should be identified on biopsy and/or microbiologic testing. (See  <a class="medical medical_review" href="/z/d/html/808.html" rel="external">"Diagnostic evaluation of suspected breast cancer"</a>.)</p><p class="headingAnchor" id="H59659186"><span class="h2">Management</span></p><p class="headingAnchor" id="H3464443291"><span class="h3">Initial approach</span><span class="headingEndMark"> — </span>Often, no specific management is necessary for IGM, especially in patients with small (&lt;5 cm), unilateral lesions without sinus formation or abscess. It is frequently a self-limiting inflammatory condition that resolves slowly; complete resolution may take 5 to 20 months [<a href="#rid57">57,58</a>]. Surgical excision for IGM is often followed by slow wound healing and is not advocated. In a series of 120 women with IGM, most cases resolved spontaneously without surgical intervention or medications [<a href="#rid58">58</a>]. A meta-analysis of 10 retrospective studies from several countries (Turkey, Iran, Saudi Arabia, Japan, and the United States) demonstrated comparable recurrence rates between patients managed with or without surgery (odds ratio 1.25, 95% CI 0.51-3.03) [<a href="#rid59">59</a>]. In some cases, treatment is warranted for infection or symptom control. </p><p>IGM complicated by secondary infection and abscess, if treated with antibiotics and drainage, usually results in complication resolution [<a href="#rid8">8,22,28,30</a>]. Antibiotic selection should be dictated by culture and susceptibility testing. We generally start an antibiotic regimen used for periductal mastitis after specimens are collected for testing and then adjust based on microbiology results. Oral regimens are generally appropriate. (See <a class="local">'Periductal mastitis'</a> above.) </p><p>If only <em>Corynebacterium</em> is recovered, the optimal management approach is uncertain, in part because of the multiple species of <em>Corynebacterium</em> and the lack of predictable susceptibility patterns. In such cases, we suggest treatment with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily). If this fails to produce a response, <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> (600 mg orally twice daily) can be used. In refractory or unusually severe cases, we favor speciating the <em>Corynebacterium </em>isolate and doing formal susceptibility testing, if available. Therapy can then be adjusted based on susceptibility testing [<a href="#rid40">40,43,60</a>]. The optimal length of therapy is also uncertain; a 5- to 7-day course can be used if the response to therapy is rapid and complete. If necessary, the duration may be extended to 10 to 14 days. While these antibiotics treat acute infection, there is little evidence that antibiotics shorten the time to full resolution of granulomatous lobular mastitis.</p><p>Localized pain may be managed with nonsteroidal anti-inflammatory drugs (NSAIDs). Routine use of steroids or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> is not warranted. These therapies can reduce swelling but may not alter the natural history of the condition, especially in those with small, localized lesions. Discontinuation has been associated with rebound inflammation [<a href="#rid28">28,52,61-65</a>]. In patients with coincident hyperprolactinemia, treatment with <a class="drug drug_general" data-topicid="9164" href="/z/d/drug information/9164.html" rel="external">bromocriptine</a>, addressing the underlying cause of excess prolactin production by surgery, or drug substitution may be beneficial [<a href="#rid39">39</a>]. </p><p class="headingAnchor" id="H2666816470"><span class="h3">Persistent or refractory symptoms</span><span class="headingEndMark"> — </span>Recurrence is common and is associated with lesion(s) size and number, skin ulceration, and the presence of fistulas [<a href="#rid66">66,67</a>]. The optimal management of patients with persistent symptoms and progression of IGM despite watchful waiting and antibiotics (if infection is present) and/or NSAIDs is uncertain; UpToDate contributors differ in their approach. Some find that treatment with steroids with or without <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> can be useful to reduce fever, pain, swelling, and possibly deformity. However, others do not use these agents, as there are no controlled studies demonstrating that they alter the natural history of the condition. Expectant management with observation has resulted in resolution of IGM in several small series [<a href="#rid30">30,58,68</a>]. </p><p>The contributors who do use steroids in this setting base the approach on the size and severity of the lesion. In patients not responding to conservative management with painful, small (&lt;5 cm) unilateral lesions with small amounts of drainage or ulceration, treatment with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (0.5 mg/kg/day) may be initiated. In patients with multiple lesions, lesions ≥5 cm in diameter, bilateral lesions, or disease with significant cutaneous ulceration, drainage, or fistulas, treatment with prednisone (0.5 to 1 mg/kg/day) may be initiated, with or without <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (10 to 15 mg orally per week, along with daily <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> supplementation) [<a href="#rid33">33,37,61,63,65,69,70</a>]. In one observational study including 19 patients with IGM, most of whom were refractory to antibiotics, steroids, and surgical intervention, use of methotrexate was associated with disease remission in 75 percent of cases [<a href="#rid69">69</a>]. There are also reports indicating that intralesional <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> and topical steroids are effective in treating this condition [<a href="#rid71">71,72</a>]. These approaches have the advantage of limiting the adverse effects of systemic steroid use.</p><p>Patients treated with steroids should begin tapering when erythema and pain have resolved (usually after about four weeks). <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> is tapered gradually over 8 to 12 weeks. If flares occur during tapering in patients on steroids alone, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (10 to 15 mg per week) may be added. If flares occur during tapering in patients on steroids and methotrexate, small increases in the methotrexate dose (by 2.5 to 5 mg every few weeks) is appropriate. Once clinical remission has been achieved, the methotrexate dose should be reduced monthly; many patients are able to discontinue therapy within 12 months [<a href="#rid73">73</a>]. Monitoring the lesions with weekly photographs may be helpful. Repeat ultrasonography may be useful if there is suspicion for new lesions or abscess reaccumulation.</p><p class="headingAnchor" id="H715168742"><span class="h1">TUBERCULOUS MASTITIS</span><span class="headingEndMark"> — </span>Tuberculous mastitis is an uncommon entity, even in countries that have a high incidence of pulmonary tuberculosis. It most commonly affects women of reproductive age, including those who are lactating; cases in men are exceedingly rare [<a href="#rid74">74-78</a>].</p><p class="headingAnchor" id="H589979564"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>The most common clinical finding is a solitary breast lump [<a href="#rid74">74-78</a>]. The lump is typically painful, ill-defined, and irregular; it is occasionally firm. Involvement of the nipple and areola is very uncommon. </p><p>Although the disease frequently involves the skin, the breast usually remains mobile on the chest wall unless there is also tuberculosis involving the underlying ribs. Both breasts are affected in up to 3 percent of patients. Common associated features are multiple sinuses, fistulous tracts, and enlarged axillary nodes, which can be matted. Tuberculous mastitis can also present with an ulcer. The overlying skin may be thickened with ulceration or sinus tracts with purulent discharge either from the ulcer or from the nipple. In later stages there may also be multiple tender areas of irregular masses, multiple sinuses and areas of pus. The sclerosing stage can lead to breast shrinkage. </p><p>Most patients have had symptoms for a few months prior to presentation, but duration of symptoms can last up to several years [<a href="#rid74">74-78</a>]. </p><p>On ultrasound, tuberculous mastitis can appear as a solitary mass or multiple masses that are well-circumscribed and grow slowly. The mass may mimic a fibroadenoma in the early stages of disease and a carcinoma in the later stages. Ultrasound may also demonstrate communications between breast lesions and fistulous tracts as well as blind ended sinuses [<a href="#rid74">74-79</a>].</p><p>Mammographic findings are generally similar to those with breast malignancies [<a href="#rid74">74-79</a>]. </p><p>There are no routine laboratory findings specific to tuberculous mastitis. </p><p class="headingAnchor" id="H1365788988"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Although it is rare, the possibility of tuberculous mastitis should be suspected in a patients with epidemiologic risk for tuberculosis who has a breast lesion that does not resolve with antibiotics, particularly if there are sinuses or fistulous tracts connecting multiple lesions. In some cases, the diagnosis is not suspected until biopsy of a lesion for the purpose of ruling out malignancy demonstrates necrotizing granulomas. The diagnosis is confirmed by growth of tuberculosis on culture of breast biopsy specimen. </p><p>Core needle biopsy of both the primary breast lesion as well as any abnormal axillary lymph nodes is essential for diagnosis. Breast masses can be initially assessed by ultrasound, which is valuable at assessing regional nodes and directing biopsies both in the breast and axilla. </p><p>When evaluating for tuberculous mastitis, one or two core tissue samples from the breast and/or axilla should be sent for acid-fast bacilli (AFB) smear and culture. Culture of pus or drainage is insufficient to detect tuberculosis, as mycobacteria in these specimens are difficult to grow. </p><p>Histologically, a finding of a granulomatous lesion with Langhans’ giant cells, is indicative of tuberculosis but cannot confirm the diagnosis. It is often difficult to demonstrate any AFB histologically. </p><p>Once the diagnosis of tuberculous mastitis is established, chest imaging should be performed to evaluate for potential pulmonary involvement. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p class="headingAnchor" id="H1514347161"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Tuberculous mastitis can been mistaken for other inflammatory conditions, including bacterial breast abscess and breast cancer. Bacterial breast abscess can be diagnosed by aspiration under ultrasound guidance followed by AFB culture and stain. Breast cancer can be distinguished by core biopsy under ultrasound guidance by pathologic diagnosis of the sample. (See  <a class="medical medical_review" href="/z/d/html/808.html" rel="external">"Diagnostic evaluation of suspected breast cancer"</a>.)</p><p class="headingAnchor" id="H99921139"><span class="h2">Management</span><span class="headingEndMark"> — </span>Once culture identifies mycobacteria, the treatment approach is similar to pulmonary tuberculosis. An initial four drug regimen (<a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">pyrazinamide</a>, and <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>) for two months is typically given, followed by an additional four months with isoniazid and rifampin, if the organism is susceptible. (See  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a>.)</p><p>Even after successful treatment of the infection, the breast can be significantly scarred and may warrant revision surgery [<a href="#rid74">74-79</a>].</p><p class="headingAnchor" id="H1001730"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Mastitis refers to inflammation of the breast tissue that may or may not be accompanied by infection. Mastitis does not necessarily occur during lactation, is not always accompanied by microbial infection, and may not resolve with antibiotics. Forms of nonlactational mastitis include periductal mastitis and idiopathic granulomatous mastitis. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Periductal mastitis</strong> – Periductal mastitis is an inflammatory condition of the subareolar ducts that usually presents with periareolar inflammation. (See <a class="local">'Periductal mastitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Occurrence of infection</strong> – Secondary infection of inflamed ducts can occur, leading to duct damage and subsequent rupture with abscess formation. A draining fistula (ie, communication between a major subareolar duct and the skin) can also develop. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Microbiology and diagnosis of infection</strong> – In the setting of purulent nipple discharge, Gram stain and culture should be obtained. Cultures are positive for pathogenic or potentially pathogenic organisms in 62 to 85 percent of cases. The most common organisms are staphylococci, enterococci, anaerobic streptococci, <em>Bacteroides</em>, and <em>Proteus</em>. (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical course and management of infection</strong> – Periductal mastitis is usually a chronic problem. Approximately half of cases resolve with antibiotic therapy together with needle aspiration or incision and drainage. Patients with repeated episodes of periareolar infection warrant surgical treatment with ductal excision. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic granulomatous mastitis (IGM)</strong> – This syndrome, also known as idiopathic granulomatous lobular mastitis, is a rare benign inflammatory breast disease of unknown etiology. IGM is most commonly seen in parous young women, often within a few years of pregnancy, although it can occur in nulliparous women. There is no increased risk of subsequent breast cancer in patients with IGM. (See <a class="local">'Idiopathic granulomatous mastitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis of IGM</strong> – The diagnosis of IGM is established via core needle biopsy of a solid mass. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of IGM</strong> – IGM associated with a localized infection usually resolves with antibiotics and drainage. Surgical excision for IGM is often followed by slow wound healing and is not advocated. The optimal management of persistent symptoms is uncertain and approaches differ. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tuberculous mastitis</strong> – Tuberculosis of the breast is an uncommon entity that affects women of reproductive age including those who are lactating. Core needle biopsy is essential for diagnosis. Histologically, a finding of a granulomatous lesion with Langhans’ giant cells is indicative of tuberculosis. Treatment is similar to that for pulmonary tuberculosis. (See <a class="local">'Tuberculous mastitis'</a> above and  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis and role of biopsy</strong> – The differential diagnosis for nonlactational mastitis includes breast cancer, which underscores the importance of biopsy in these cases, especially if there is uncertainty or lack of response to therapy. (See  <a class="medical medical_review" href="/z/d/html/808.html" rel="external">"Diagnostic evaluation of suspected breast cancer"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Dixon JM. Breast infection. In: ABC of Breast Diseases, Dixon JM (Ed), Blackwell Publishing, Oxford 2006. p.19.</li><li><a class="nounderline abstract_t">Dixon JM, Ravisekar O, Chetty U, Anderson TJ. Periductal mastitis and duct ectasia: different conditions with different aetiologies. Br J Surg 1996; 83:820.</a></li><li><a class="nounderline abstract_t">Schäfer P, Fürrer C, Mermillod B. An association of cigarette smoking with recurrent subareolar breast abscess. Int J Epidemiol 1988; 17:810.</a></li><li><a class="nounderline abstract_t">Bundred NJ, Dover MS, Coley S, Morrison JM. Breast abscesses and cigarette smoking. Br J Surg 1992; 79:58.</a></li><li><a class="nounderline abstract_t">Hill P, Wynder EL. Nicotine and cotinine in breast fluid. Cancer Lett 1979; 6:251.</a></li><li><a class="nounderline abstract_t">ZUSKA JJ, CRILE G Jr, AYRES WW. Fistulas of lactifierous ducts. Am J Surg 1951; 81:312.</a></li><li><a class="nounderline abstract_t">Lannin DR. Twenty-two year experience with recurring subareolar abscess andlactiferous duct fistula treated by a single breast surgeon. Am J Surg 2004; 188:407.</a></li><li class="breakAll">Dixon JM, Bundred NJ. Management of disorders of the ductal system and infections. In: Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Osborne CK (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. p.47.</li><li><a class="nounderline abstract_t">Dixon JM. Periductal mastitis and duct ectasia: an update. The Breast 1998; 7:128.</a></li><li><a class="nounderline abstract_t">Dixon JM, Thompson AM. Effective surgical treatment for mammary duct fistula. Br J Surg 1991; 78:1185.</a></li><li><a class="nounderline abstract_t">Gollapalli V, Liao J, Dudakovic A, et al. Risk factors for development and recurrence of primary breast abscesses. J Am Coll Surg 2010; 211:41.</a></li><li><a class="nounderline abstract_t">Bharat A, Gao F, Aft RL, et al. Predictors of primary breast abscesses and recurrence. World J Surg 2009; 33:2582.</a></li><li><a class="nounderline abstract_t">Dixon JM. Periductal mastitis/duct ectasia. World J Surg 1989; 13:715.</a></li><li><a class="nounderline abstract_t">Greydanus DE, Matytsina L, Gains M. Breast disorders in children and adolescents. Prim Care 2006; 33:455.</a></li><li><a class="nounderline abstract_t">Browning J, Bigrigg A, Taylor I. Symptomatic and incidental mammary duct ectasia. J R Soc Med 1986; 79:715.</a></li><li><a class="nounderline abstract_t">Schwartz GF. Benign neoplasms and "inflammations" of the breast. Clin Obstet Gynecol 1982; 25:373.</a></li><li><a class="nounderline abstract_t">Bundred NJ, Dixon JM, Lumsden AB, et al. Are the lesions of duct ectasia sterile? Br J Surg 1985; 72:844.</a></li><li><a class="nounderline abstract_t">Ammari FF, Yaghan RJ, Omari AK. Periductal mastitis. Clinical characteristics and outcome. Saudi Med J 2002; 23:819.</a></li><li><a class="nounderline abstract_t">Rahal RM, Júnior RF, Reis C, et al. Prevalence of bacteria in the nipple discharge of patients with duct ectasia. Int J Clin Pract 2005; 59:1045.</a></li><li><a class="nounderline abstract_t">Taffurelli M, Pellegrini A, Santini D, et al. Recurrent periductal mastitis: Surgical treatment. Surgery 2016; 160:1689.</a></li><li><a class="nounderline abstract_t">Dixon J, Lee E, Greenall M. Treatment of periareolar inflammation associated with periductal mastitis using metronidazole and flucloxacillin: A preliminary report. Br J Clin Pract 1988; 42:78.</a></li><li><a class="nounderline abstract_t">Dixon JM. Breast abscess. Br J Hosp Med (Lond) 2007; 68:315.</a></li><li><a class="nounderline abstract_t">Komenaka IK, Pennington RE Jr, Bowling MW, et al. A technique to prevent recurrence of lactiferous duct fistula. J Am Coll Surg 2006; 203:253.</a></li><li><a class="nounderline abstract_t">Almasad JK. Mammary duct fistulae: classification and management. ANZ J Surg 2006; 76:149.</a></li><li class="breakAll">Meguid M, Kort K, Numann P, Oler A. Subareolar breast abscess: The penultimate stage of the mammary duct-associated inflammatory disease sequence. In: The Breast, 4th ed, Bland K, Copeland III E (Eds), Elsevier, Philadelphia 2009. Vol 1, p.107.</li><li><a class="nounderline abstract_t">PATEY DH, THACKRAY AC. Pathology and treatment of mammary-duct fistula. Lancet 1958; 2:871.</a></li><li class="breakAll">Dixon JM. Breast surgery. In: Infection in surgical practice, Taylor EW (Ed), Oxford Medical Publications, Oxford 1992. p.187.</li><li><a class="nounderline abstract_t">Wilson JP, Massoll N, Marshall J, et al. Idiopathic granulomatous mastitis: in search of a therapeutic paradigm. Am Surg 2007; 73:798.</a></li><li><a class="nounderline abstract_t">Going JJ, Anderson TJ, Wilkinson S, Chetty U. Granulomatous lobular mastitis. J Clin Pathol 1987; 40:535.</a></li><li><a class="nounderline abstract_t">Al-Khaffaf B, Knox F, Bundred NJ. Idiopathic granulomatous mastitis: a 25-year experience. J Am Coll Surg 2008; 206:269.</a></li><li><a class="nounderline abstract_t">Maffini F, Baldini F, Bassi F, et al. Systemic therapy as a first choice treatment for idiopathic granulomatous mastitis. J Cutan Pathol 2009; 36:689.</a></li><li><a class="nounderline abstract_t">Tuli R, O'Hara BJ, Hines J, Rosenberg AL. Idiopathic granulomatous mastitis masquerading as carcinoma of the breast: a case report and review of the literature. Int Semin Surg Oncol 2007; 4:21.</a></li><li><a class="nounderline abstract_t">Néel A, Hello M, Cottereau A, et al. Long-term outcome in idiopathic granulomatous mastitis: a western multicentre study. QJM 2013; 106:433.</a></li><li><a class="nounderline abstract_t">Barreto DS, Sedgwick EL, Nagi CS, Benveniste AP. Granulomatous mastitis: etiology, imaging, pathology, treatment, and clinical findings. Breast Cancer Res Treat 2018; 171:527.</a></li><li><a class="nounderline abstract_t">Hovanessian Larsen LJ, Peyvandi B, Klipfel N, et al. Granulomatous lobular mastitis: imaging, diagnosis, and treatment. AJR Am J Roentgenol 2009; 193:574.</a></li><li><a class="nounderline abstract_t">Nguyen MH, Molland JG, Kennedy S, et al. Idiopathic granulomatous mastitis: case series and clinical review. Intern Med J 2021; 51:1791.</a></li><li><a class="nounderline abstract_t">Pandey TS, Mackinnon JC, Bressler L, et al. Idiopathic granulomatous mastitis--a prospective study of 49 women and treatment outcomes with steroid therapy. Breast J 2014; 20:258.</a></li><li><a class="nounderline abstract_t">Nikolaev A, Blake CN, Carlson DL. Association between Hyperprolactinemia and Granulomatous Mastitis. Breast J 2016; 22:224.</a></li><li><a class="nounderline abstract_t">Li J, McGregor HP. Idiopathic granulomatous mastitis associated with hyperprolactinemia: A nonoperative approach. Breast J 2017; 23:742.</a></li><li><a class="nounderline abstract_t">Tauch A, Fernández-Natal I, Soriano F. A microbiological and clinical review on Corynebacterium kroppenstedtii. Int J Infect Dis 2016; 48:33.</a></li><li><a class="nounderline abstract_t">Taylor GB, Paviour SD, Musaad S, et al. A clinicopathological review of 34 cases of inflammatory breast disease showing an association between corynebacteria infection and granulomatous mastitis. Pathology 2003; 35:109.</a></li><li><a class="nounderline abstract_t">Troxell ML, Gordon NT, Doggett JS, et al. Cystic Neutrophilic Granulomatous Mastitis:  Association With Gram-Positive Bacilli and Corynebacterium. Am J Clin Pathol 2016; 145:635.</a></li><li><a class="nounderline abstract_t">Dobinson HC, Anderson TP, Chambers ST, et al. Antimicrobial Treatment Options for Granulomatous Mastitis Caused by Corynebacterium Species. J Clin Microbiol 2015; 53:2895.</a></li><li><a class="nounderline abstract_t">Johnstone KJ, Robson J, Cherian SG, et al. Cystic neutrophilic granulomatous mastitis associated with Corynebacterium including Corynebacterium kroppenstedtii. Pathology 2017; 49:405.</a></li><li><a class="nounderline abstract_t">Wong SCY, Poon RWS, Chen JHK, et al. Corynebacterium kroppenstedtii Is an Emerging Cause of Mastitis Especially in Patients With Psychiatric Illness on Antipsychotic Medication. Open Forum Infect Dis 2017; 4:ofx096.</a></li><li><a class="nounderline abstract_t">Lai EC, Chan WC, Ma TK, et al. The role of conservative treatment in idiopathic granulomatous mastitis. Breast J 2005; 11:454.</a></li><li><a class="nounderline abstract_t">Kessler E, Wolloch Y. Granulomatous mastitis: a lesion clinically simulating carcinoma. Am J Clin Pathol 1972; 58:642.</a></li><li><a class="nounderline abstract_t">Han BK, Choe YH, Park JM, et al. Granulomatous mastitis: mammographic and sonographic appearances. AJR Am J Roentgenol 1999; 173:317.</a></li><li><a class="nounderline abstract_t">Fletcher A, Magrath IM, Riddell RH, Talbot IC. Granulomatous mastitis: a report of seven cases. J Clin Pathol 1982; 35:941.</a></li><li><a class="nounderline abstract_t">Gombos EC, et al. Granulomatous mastitis. J Women's Imaging 2004; 6:136.</a></li><li><a class="nounderline abstract_t">Ozurk M, et al. Granulomatous mastitis: Radiologic findings. Acta Radiologica 1997; 48:150.</a></li><li><a class="nounderline abstract_t">Aldaqal SM. Idiopathic granulomatous mastitis. Clinical presentation, radiological features and treatment. Saudi Med J 2004; 25:1884.</a></li><li><a class="nounderline abstract_t">Memis A, Bilgen I, Ustun EE, et al. Granulomatous mastitis: imaging findings with histopathologic correlation. Clin Radiol 2002; 57:1001.</a></li><li><a class="nounderline abstract_t">Sabaté JM, Clotet M, Gómez A, et al. Radiologic evaluation of uncommon inflammatory and reactive breast disorders. Radiographics 2005; 25:411.</a></li><li><a class="nounderline abstract_t">Yilmaz E, Lebe B, Usal C, Balci P. Mammographic and sonographic findings in the diagnosis of idiopathic granulomatous mastitis. Eur Radiol 2001; 11:2236.</a></li><li><a class="nounderline abstract_t">Koksal H. The Clinical Utility of Autoantibodies in Patients with Idiopathic Granulomatous Mastitis. J Invest Surg 2022; 35:325.</a></li><li><a class="nounderline abstract_t">Bouton ME, Jayaram L, O'Neill PJ, et al. Management of idiopathic granulomatous mastitis with observation. Am J Surg 2015; 210:258.</a></li><li><a class="nounderline abstract_t">Davis J, Cocco D, Matz S, et al. Re-evaluating if observation continues to be the best management of idiopathic granulomatous mastitis. Surgery 2019; 166:1176.</a></li><li><a class="nounderline abstract_t">Zhou F, Liu L, Liu L, et al. Comparison of Conservative versus Surgical Treatment Protocols in Treating Idiopathic Granulomatous Mastitis: A Meta-Analysis. Breast Care (Basel) 2020; 15:415.</a></li><li><a class="nounderline abstract_t">Neemuchwala A, Soares D, Ravirajan V, et al. In Vitro Antibiotic Susceptibility Pattern of Non-diphtheriae Corynebacterium Isolates in Ontario, Canada, from 2011 to 2016. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Naraynsingh V, Hariharan S, Dan D, et al. Conservative management for idiopathic granulomatous mastitis mimicking carcinoma: case reports and literature review. Breast Dis 2010; 31:57.</a></li><li><a class="nounderline abstract_t">Munot K, Nicholson S, Birkett V. Granulomatous mastitis - A novel method of treatment. Eur J Surg Oncol 2012; 38:461.</a></li><li><a class="nounderline abstract_t">Akbulut S, Arikanoglu Z, Senol A, et al. Is methotrexate an acceptable treatment in the management of idiopathic granulomatous mastitis? Arch Gynecol Obstet 2011; 284:1189.</a></li><li><a class="nounderline abstract_t">Schmajuk G, Genovese MC. First report of idiopathic granulomatous mastitis treated with methotrexate monotherapy. J Rheumatol 2009; 36:1559.</a></li><li><a class="nounderline abstract_t">Sheybani F, Sarvghad M, Naderi HR, Gharib M. Treatment for and clinical characteristics of granulomatous mastitis. Obstet Gynecol 2015; 125:801.</a></li><li><a class="nounderline abstract_t">Yılmaz TU, Gürel B, Güler SA, et al. Scoring Idiopathic Granulomatous Mastitis: An Effective System for Predicting Recurrence? Eur J Breast Health 2018; 14:112.</a></li><li><a class="nounderline abstract_t">Basim P, Argun D, Argun F. Risk Factors for Idiopathic Granulomatous Mastitis Recurrence after Patient-Tailored Treatment: Do We Need an Escalating Treatment Algorithm? Breast Care (Basel) 2022; 17:172.</a></li><li><a class="nounderline abstract_t">Yukawa M, Watatani M, Isono S, et al. Management of granulomatous mastitis: a series of 13 patients who were evaluated for treatment without corticosteroids. Int Surg 2015; 100:774.</a></li><li><a class="nounderline abstract_t">Postolova A, Troxell ML, Wapnir IL, Genovese MC. Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis. J Rheumatol 2020; 47:924.</a></li><li><a class="nounderline abstract_t">Kehribar DY, Duran TI, Polat AK, Ozgen M. Effectiveness of Methotrexate in Idiopathic Granulomatous Mastitis Treatment. Am J Med Sci 2020; 360:560.</a></li><li><a class="nounderline abstract_t">Altintoprak F, Kivilcim T, Yalkin O, et al. Topical Steroids Are Effective in the Treatment of Idiopathic Granulomatous Mastitis. World J Surg 2015; 39:2718.</a></li><li><a class="nounderline abstract_t">Kim BS, Koo BY, Eom TI. Usefulness of ultrasound-guided intralesional steroid in management of idiopathic granulomatous mastitis. J Surg Ultrasound 2016; 3:4045.</a></li><li><a class="nounderline abstract_t">Akbulut S, Yilmaz D, Bakir S. Methotrexate in the management of idiopathic granulomatous mastitis: review of 108 published cases and report of four cases. Breast J 2011; 17:661.</a></li><li><a class="nounderline abstract_t">Marinopoulos S, Lourantou D, Gatzionis T, et al. Breast tuberculosis: Diagnosis, management and treatment. Int J Surg Case Rep 2012; 3:548.</a></li><li><a class="nounderline abstract_t">Farrokh D, Alamdaran A, Feyzi Laeen A, et al. Tuberculous mastitis: A review of 32 cases. Int J Infect Dis 2019; 87:135.</a></li><li><a class="nounderline abstract_t">Baharoon S. Tuberculosis of the breast. Ann Thorac Med 2008; 3:110.</a></li><li><a class="nounderline abstract_t">Tewari M, Shukla HS. Breast tuberculosis: diagnosis, clinical features &amp; management. Indian J Med Res 2005; 122:103.</a></li><li><a class="nounderline abstract_t">Banerjee SN, Ananthakrishnan N, Mehta RB, Parkash S. Tuberculous mastitis: a continuing problem. World J Surg 1987; 11:105.</a></li><li><a class="nounderline abstract_t">Longman CF, Campion T, Butler B, et al. Imaging features and diagnosis of tuberculosis of the breast. Clin Radiol 2017; 72:217.</a></li></ol></div><div id="topicVersionRevision">Topic 794 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Dixon JM. Breast infection. In: ABC of Breast Diseases, Dixon JM (Ed), Blackwell Publishing, Oxford 2006. p.19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8696751" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Periductal mastitis and duct ectasia: different conditions with different aetiologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3225089" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : An association of cigarette smoking with recurrent subareolar breast abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1737279" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Breast abscesses and cigarette smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/436120" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nicotine and cotinine in breast fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14819475" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fistulas of lactifierous ducts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15474436" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Twenty-two year experience with recurring subareolar abscess andlactiferous duct fistula treated by a single breast surgeon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15474436" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Twenty-two year experience with recurring subareolar abscess andlactiferous duct fistula treated by a single breast surgeon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Periductal mastitis and duct ectasia: an update</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1958980" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effective surgical treatment for mammary duct fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610247" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Risk factors for development and recurrence of primary breast abscesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19669231" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Predictors of primary breast abscesses and recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2696225" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Periductal mastitis/duct ectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16713771" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Breast disorders in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3806542" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Symptomatic and incidental mammary duct ectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6286199" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Benign neoplasms and "inflammations" of the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4041720" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Are the lesions of duct ectasia sterile?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12174233" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Periductal mastitis. Clinical characteristics and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16115180" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prevalence of bacteria in the nipple discharge of patients with duct ectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27616631" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Recurrent periductal mastitis: Surgical treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment of periareolar inflammation associated with periductal mastitis using metronidazole and flucloxacillin: A preliminary report</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17639835" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Breast abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864039" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A technique to prevent recurrence of lactiferous duct fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16626355" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mammary duct fistulae: classification and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16626355" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mammary duct fistulae: classification and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13589030" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pathology and treatment of mammary-duct fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13589030" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pathology and treatment of mammary-duct fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17879688" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Idiopathic granulomatous mastitis: in search of a therapeutic paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3584506" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Granulomatous lobular mastitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18222379" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Idiopathic granulomatous mastitis: a 25-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19222698" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Systemic therapy as a first choice treatment for idiopathic granulomatous mastitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17662130" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Idiopathic granulomatous mastitis masquerading as carcinoma of the breast: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23407345" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-term outcome in idiopathic granulomatous mastitis: a western multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29971624" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Granulomatous mastitis: etiology, imaging, pathology, treatment, and clinical findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620458" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Granulomatous lobular mastitis: imaging, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34713960" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Idiopathic granulomatous mastitis: case series and clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24673796" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Idiopathic granulomatous mastitis--a prospective study of 49 women and treatment outcomes with steroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26705962" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Association between Hyperprolactinemia and Granulomatous Mastitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28845595" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Idiopathic granulomatous mastitis associated with hyperprolactinemia: A nonoperative approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27155209" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A microbiological and clinical review on Corynebacterium kroppenstedtii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12745457" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A clinicopathological review of 34 cases of inflammatory breast disease showing an association between corynebacteria infection and granulomatous mastitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27247368" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cystic Neutrophilic Granulomatous Mastitis: Association With Gram-Positive Bacilli and Corynebacterium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26135858" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Antimicrobial Treatment Options for Granulomatous Mastitis Caused by Corynebacterium Species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28442140" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cystic neutrophilic granulomatous mastitis associated with Corynebacterium including Corynebacterium kroppenstedtii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28852671" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Corynebacterium kroppenstedtii Is an Emerging Cause of Mastitis Especially in Patients With Psychiatric Illness on Antipsychotic Medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16297091" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The role of conservative treatment in idiopathic granulomatous mastitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4674439" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Granulomatous mastitis: a lesion clinically simulating carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430126" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Granulomatous mastitis: mammographic and sonographic appearances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6889612" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Granulomatous mastitis: a report of seven cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Granulomatous mastitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Granulomatous mastitis: Radiologic findings</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15711659" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Idiopathic granulomatous mastitis. Clinical presentation, radiological features and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12409111" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Granulomatous mastitis: imaging findings with histopathologic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15798059" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Radiologic evaluation of uncommon inflammatory and reactive breast disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11702165" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Mammographic and sonographic findings in the diagnosis of idiopathic granulomatous mastitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33327830" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The Clinical Utility of Autoantibodies in Patients with Idiopathic Granulomatous Mastitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25746911" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Management of idiopathic granulomatous mastitis with observation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31400951" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Re-evaluating if observation continues to be the best management of idiopathic granulomatous mastitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32982653" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparison of Conservative versus Surgical Treatment Protocols in Treating Idiopathic Granulomatous Mastitis: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29339389" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : In Vitro Antibiotic Susceptibility Pattern of Non-diphtheriae Corynebacterium Isolates in Ontario, Canada, from 2011 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21109722" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Conservative management for idiopathic granulomatous mastitis mimicking carcinoma: case reports and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Granulomatous mastitis - A novel method of treatment</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21207047" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Is methotrexate an acceptable treatment in the management of idiopathic granulomatous mastitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19567642" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : First report of idiopathic granulomatous mastitis treated with methotrexate monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25751209" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Treatment for and clinical characteristics of granulomatous mastitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29774320" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Scoring Idiopathic Granulomatous Mastitis: An Effective System for Predicting Recurrence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35707181" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Risk Factors for Idiopathic Granulomatous Mastitis Recurrence after Patient-Tailored Treatment: Do We Need an Escalating Treatment Algorithm?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26011195" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Management of granulomatous mastitis: a series of 13 patients who were evaluated for treatment without corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31203215" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32635989" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effectiveness of Methotrexate in Idiopathic Granulomatous Mastitis Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26148520" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Topical Steroids Are Effective in the Treatment of Idiopathic Granulomatous Mastitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Usefulness of ultrasound-guided intralesional steroid in management of idiopathic granulomatous mastitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21951547" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Methotrexate in the management of idiopathic granulomatous mastitis: review of 108 published cases and report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22918083" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Breast tuberculosis: Diagnosis, management and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31442629" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Tuberculous mastitis: A review of 32 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19561892" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Tuberculosis of the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16177466" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Breast tuberculosis: diagnosis, clinical features&amp;management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3811379" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Tuberculous mastitis: a continuing problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28065639" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Imaging features and diagnosis of tuberculosis of the breast.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
